Samuel Prater

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

UAMS

Also affiliated: Memorial Hermann (2018–2020); RELX Group (Netherlands) (2019); Texas Medical Center (2022–2024); Emory University (2020); Cotton (United States) (2019); Harris Health System (2020); Associated Press (2019); Hanby Environmental (United States) (2016); Lyndon Baines Johnson Hospital (2020); The University of Texas Health Science Center (2019–2024); University of Houston (2019); The University of Texas Health Science Center at Houston (2018–2024); Bryan College (2019)

Faculty Researcher

11 h-index 24 pubs 591 cited

Research Areas

Biomedical Subjects

OverviewAI-generated summary

Samuel Prater's research focuses on the use of ketamine for acute pain management in trauma patients, as evidenced by his involvement in the KAPT randomized controlled trial and its subsequent pragmatic trial publication. His work also addresses public health issues within emergency departments, including the impact of the COVID-19 pandemic on routine HIV screening and the implications of indeterminate HIV test results. Prater has also investigated integrated bridge treatment programs for opioid use disorder. His scholarly output includes 24 publications, with an h-index of 11 and over 576 citations, indicating recent activity in his fields of study.

Metrics

h-index: 11
Publications: 24
Citations: 591

Selected Publications

Ketamine for acute pain after trauma: A pragmatic, randomized clinical trial (2024)

The Journal of Trauma: Injury, Infection, and Critical Care 5 citations DOI OpenAlex

View all publications on OpenAlex →